Szpiczak mnogi: badanie fazy III leku pomalidomide i dexamethasone
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Poznań. Najwięcej badań dotyczy: nowotwór, rak płuca, niedrobnokomórkowy rak płuca, choroba sercowo-naczyniowa.
601 badań: 558 rekrutuje, 43 wkrótce zaczną.
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
European Disease Registry on Retinopathy of Prematurity (ROP)
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated…
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Polish Multicenter PERTs PE Outcomes Registry
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Secukinumab Open Label Roll-over Extension Protocol
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in…
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
Trifecta-Kidney cfDNA-MMDx Study
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients…
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
Pan Tumor Rollover Study
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 17 listopada 2026.